Effects of Boswellia serrata in mouse models of chemically induced colitis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 288, Issue 4 51-4, 2005, Pages

  Kiela, Pawel R ^a   Midura, Anna J ^a   Kuscuoglu, Nesrin ^a   Jolad, Shivanand D ^b,c   Sólyom, Anikó M ^b,c   Besselsen, David G ^d   Timmermann, Barbara N ^b,c   Ghishan, Fayez K ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b Arizona Ctr for Phytomedicine Res   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

Dextran sulfate; Liver; Microarray; Steatosis; Trinitrobenzene sulfonic acid

Indexed keywords

11 KETO BETA BOSWELLIC ACID; 3 ACETYL 11 KETO BETA BOSWELLIC ACID; 3 ACETYL ALPHA BOSWELLIC ACID; 3 ACETYL BETA BOSWELLIC ACID; ALPHA BOSWELLIC ACID; ANTIINFLAMMATORY AGENT; BETA BOSWELLIC ACID; BOSWELLIA EXTRACT; BOSWELLIC ACID; DEXTRAN SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; PLANT EXTRACT; RESAZURIN; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOSWELLIA; CELL PROLIFERATION; CELL STRAIN HEPG2; COLITIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DETOXIFICATION; DIET SUPPLEMENTATION; DNA MICROARRAY; DRUG EFFECT; DRUG EFFICACY; FATTY LIVER; GENE EXPRESSION; GENE NUMBER; HEPATOMEGALY; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; LIPID METABOLISM; LIPIDOSIS; LIVER TOXICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STEROID METABOLISM; WEIGHT REDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BOSWELLIA; CACO-2 CELLS; CELL DIVISION; COLITIS; DEXTRAN SULFATE; GENE EXPRESSION; HUMANS; INTESTINAL MUCOSA; LIVER; MICE; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGAN SIZE; PLANT EXTRACTS; TRINITROBENZENESULFONIC ACID; TRITERPENES; WEIGHT LOSS;

EID: 15244359179     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.00433.2004     Document Type: Article

References (50)

1. Abbaszade IG, Clarke TR, Park CH, and Payne AH. The mouse 3 β-hydroxysteroid dehydrogenase multigene family includes two functionally distinct groups of proteins. Mol Endocrinol 9: 1214-1222, 1995.
2. Ammon HP, Safayhi H, Mack T, and Sabieraj J. Mechanism of antiinflammatory actions of curcumine and boswellic acids. J Ethnopharmacol 38: 113-119, 1993.
3. Buchele B, Zugmaier W, and Simmet T. Analysis of pentacyclic triterpenic acids from frankincense gum resins and related phytopharmaceuticals by high-performance liquid chromatography. Identification of lupeolic acid, a novel pentacyclic triterpene. J Chromatogr B Analyt Technol Biomed Life Sci 791: 21-30, 2003.
4. Burgmann T, Rawsthorne P, and Bernstein CN. Predictors of alternative and complementary medicine use in inflammatory bowel disease: do measures of conventional health care utilization relate to use? Am J Gastroenterol 99: 889-893, 2004.
5. Dreyling KW, Kozuschek W, Schaarschmidt K, Goebell H, and Peskar BM. Role of the endogenous leukotriene system in chronic inflammatory bowel disease. Prog Clin Biol Res 242: 309-315, 1987.
6. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, and Kessler RC. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280: 1569-1575, 1998.
7. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, and Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 328: 246-252, 1993.
8. Galy AH, Hadden EM, Touraine JL, and Hadden JW. Effects of cytokines on human thymic epithelial cells in culture: IL1 induces thymic epithelial cell proliferation and change in morphology. Cell Immunol 124: 13-27, 1989.
9. Gerhardt H, Seifert F, Buvari P, Vogelsang H, and Repges R. Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol 39: 11-17, 2001. [In German]
10. Gupta I, Gupta V, Parihar A, Gupta S, Ludtke R, Safayhi H, and Ammon HP. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res 3: 511-514, 1998.
11. Gupta I, Parihar A, Malhotra P, Gupta S, Ludtke R, Safayhi H, and Ammon HP. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 67: 391-395, 2001.
12. Gupta I, Parihar A, Malhotra P, Singh GB, Ludtke R, Safayhi H, and Ammon HP. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 2: 37-43, 1997.
13. Hawkey CJ, Dube LM, Rountree LV, Linnen PJ, and Lancaster JF. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis. Gastroenterology 112: 718-724, 1997.
14. Hillingso J, Kjeldsen J, Laursen LS, Lauritsen K, von Spreckelsen S, Depre M, Friedman BS, Malmstrom K, Shingo S, Bukhave K, and Rask-Madsen J. Blockade of leukotriene production by a single oral dose of MK-0591 in active ulcerative colitis. Clin Pharmacol Ther 57: 335-341, 1995.
15. Hilsden RJ, Meddings JB, and Verhoef MJ. Complementary and alternative medicine use by patients with inflammatory bowel disease: an Internet survey. Can J Gastroenterol 13: 327-332, 1999.
16. Hilsden RJ, Scott CM, and Verhoef MJ. Complementary medicine use by patients with inflammatory bowel disease. Am J Gastroenterol 93: 697-701, 1998.
17. Hoernlein RF, Orlikowsky T, Zehrer C, Niethammer D, Sailer ER, Simmet T, Dannecker GE, and Ammon HP. Acetyl-11-keto-β-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I. J Pharmacol Exp Ther 288: 613-619, 1999.
18. Kirtikar KRBB. Indian Medicinal Plants. Delhi, India: Periodical Experts, 1935.
19. Krieglstein CF, Anthoni C, Rijcken EJ, Laukotter M, Spiegel HU, Boden SE, Schweizer S, Safayhi H, Senninger N, and Schurmann G. Acetyl-11-keto-β- boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int J Colorectal Dis 16: 88-95, 2001.
20. Kulkarni RR, Patki PS, Jog VP, Gandage SG, and Patwardhan B. Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study. J Ethnopharmacol 33: 91-95, 1991.
21. Langmead L, Chitnis M, and Rampton DS. Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflamm Bowel Dis 8: 174-179, 2002.
22. 4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 91: 837-844, 1986.
23. Laursen LS, Naesdal J, Bukhave K, Lauritsen K, and Rask-Madsen J. Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet 335: 683-685, 1990.
24. Lipkin M. Proliferation and differentiation of normal and diseased gastrointestinal cells. In: Physiology of the Gastrointestinal Tract (2nd ed.), edited by Johnson LR. New York: Raven, 1987, p. 255-285.
25. 4. Dig Dis Sci 32: 1380-1388, 1987.
26. McMillian MK, Grant ER, Zhong Z, Parker JB, Li L, Zivin RA, Burczynski ME, and Johnson MD. Nile Red binding to HepG2 cells: an improved assay for in vitro studies of hepatosteatosis. In Vitr Mol Toxicol 14: 177-190, 2001.
27. Moser G, Tillinger W, Sachs G, Maier-Dobersberger T, Wyatt J, Vogelsang H, Lochs H, and Gangl A. Relationship between the use of unconventional therapies and disease-related concerns: a study of patients with inflammatory bowel disease. J Psychosom Res 40: 503-509, 1996.
28. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, and Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702, 1990.
29. Postlethwaite AE, Lachman LB, and Kang AH. Induction of fibroblast proliferation by interleukin-1 derived from human monocytic leukemia cells. Arthritis Rheum 27: 995-1001, 1984.
30. Quattropani C, Ausfeld B, Straumann A, Heer P, and Seibold F. Complementary alternative medicine in patients with inflammatory bowel disease: use and attitudes. Scand J Gastroenterol 38: 277-282, 2003.
31. Rawsthorne P, Shanahan F, Cronin NC, Anton PA, Lofberg R, Bohman L, and Bernstein CN. An international survey of the use and attitudes regarding alternative medicine by patients with inflammatory bowel disease. Am J Gastroenterol 94: 1298-1303, 1999.
32. Roberts WG, Simon TJ, Berlin RG, Haggitt RC, Snyder ES, Stenson WF, Hanauer SB, Reagan JE, Cagliola A, Tanaka WK, Simon S, and Berger ML. Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology 112: 725-732, 1997.
33. Sacerdoti D, Gatta A, and McGiff JC. Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology. Prostaglandins Other Lipid Mediat 72: 51-71, 2003.
34. Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, and Ammon HP. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 261: 1143-1146, 1992.
35. Safayhi H, Rall B, Sailer ER, and Ammon HP. Inhibition by boswellic acids of human leukocyte elastase. J Pharmacol Exp Ther 281: 460-463, 1997.
36. Sailer ER, Subramanian LR, Rall B, Hoernlein RF, Ammon HP, and Safayhi H. Acetyl-11-keto-β-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. Br J Pharmacol 117: 615-618, 1996.
37. Sander O, Herborn G, and Rau R. Is H15 (resin extract of Boswellia serrata, "incense") a useful supplement to established drug therapy of chronic polyarthritis? Results of a double-blind pilot study. Z Rheumatol 57: 11-16, 1998. [In German]
38. Sauder DN, Kilian PL, McLane JA, Quick TW, Jakubovic H, Davis SC, Eaglstein WH, and Mertz PM. Interleukin-1 enhances epidermal wound healing. Lymphokine Res 9: 465-473, 1990.
39. Scott CM, Verhoef MJ, and Hilsden RJ. Inflammatory bowel disease patients' decisions to use complementary therapies: links to existing models of care. Complement Ther Med 11: 22-27, 2003.
40. Sharon P and Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 86: 453-460, 1984.
41. Street ME, Miraki-Moud F, Sanderson IR, Savage MO, Giovannelli G, Bernasconi S, and Camacho-Hubner C. Interleukin-1β (IL-1β) and IL-6 modulate insulin-like growth factor-binding protein (IGFBP) secretion in colon cancer epithelial (Caco-2) cells. J Endocrinol 179: 405-415, 2003.
42. Syrovets T, Buchele B, Gedig E, Slupsky JR, and Simmet T. Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIα. Mol Pharmacol 58: 71-81, 2000.
43. Varilek GW, Neil GA, and Bishop WP. Caco-2 cells express type I interleukin-1 receptors: ligand binding enhances proliferation. Am J Physiol Gastrointest Liver Physiol 267: G1101-G1107, 1994.
44. Verhoef MJ, Scott CM, and Hilsden RJ. A multimethod research study on the use of complementary therapies among patients with inflammatory bowel disease. Altern Ther Health Med 4: 68-71, 1998.
45. Wallace JL and Keenan CM. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol Gastrointest Liver Physiol 258: G527-G534, 1990.
46. Wallace JL, MacNaughton WK, Morris GP, and Beck PL. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96: 29-36, 1989.
47. Wang H, Zhao Y, Bradbury JA, Graves JP, Foley J, Blaisdell JA, Goldstein JA, and Zeldin DC. Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities. Mol Pharmacol 65: 1148-1158, 2004.
48. Wildfeuer A, Neu IS, Safayhi H, Metzger G, Wehrmann M, Vogel U, and Ammon HP. Effects of boswellic acids extracted from a herbal medicine on the biosynthesis of leukotrienes and the course of experimental autoimmune encephalomyelitis. Arzneimittelforschung 48: 668-674, 1998.
49. Yabe D, Brown MS, and Goldstein JL. Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. Proc Natl Acad Sci USA 99: 12753-12758, 2002.
50. Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, Yeldandi AV, Rao MS, Gonzalez FJ, and Reddy JK. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor γ1 (PPAR-γ1) overexpression. J Biol Chem 278: 498-505, 2003.